Publication | Closed Access

A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

Esophageal CancerMedicineCancer ManagementRecurrent Esophageal CancerPathologyWeekly 1-H InfusionPhase Ii StudyCancer TreatmentOncologyRadiation OncologyCancer Research